Increasing prevalence of immunodeficiency disorder is expected to drive the growth of global plasma fractionation in the forecast period, 2024-2028.
According to TechSci Research report, “Plasma Fractionation Market – Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028”, Plasma Fractionation Market is anticipated to grow at an impressive rate in the forecast period, 2024-2028. This can be ascribed to the increasing prevalence of autoimmune diseases such as graves disease, and Hashimoto thyroiditis due to smoking, obesity, exposure to toxins, and having relatives with autoimmune diseases and inflammatory disorders among the population across the globe. Additionally, increasing investment by government organizations to develop cost-effective products for immunodeficiency disorder treatment, especially in the developed countries in North America and Europe is expected to create lucrative opportunities for market growth in coming years. Besides, increasing research and development activities in the healthcare industry regarding immunology are further expected to support the market growth. Similarly, a growing number of diagnosed patients due to the clinical need for immunoglobulin is expected to create significant growth in the market during the forecast period. Also, growing demand for the usage of albumin in various applications such as cardiovascular diseases, sepsis, and cirrhosis can boost the market growth during the forecast period.
However, the high cost of plasma-derived product can create affordability issues thereby slowing down the growth of the global plasma fractionation market in the forecast period. Similarly, high risks and complications associated with treatments by plasma may hamper the plasma fractionation market growth during the forecast period Also, poor reimbursement scenario for the treatment of immunodeficiency disorder in the developing region is further expected to create a significant growth during the forecast period.
Browse over XX market data Figures spread through XX Pages and an in-depth TOC on “Global Plasma Fractionation Market“.
Based on product, the global plasma fractionation market can be segmented into Albumin, Immunoglobulins, Coagulation Factors, Protease Inhibitors, Others. The coagulation factors segment dominated the market in 2022 and is expected to continue maintaining its dominance throughout the forecast period. This can be ascribed to increase the approval of new medications and the high frequency of bleeding diseases. Also, growing accidents and trauma cases can drive the growth of the market during the forecast period.
Based on application, the market can be segmented into Neurology, Hematology, Oncology, Immunology, and Others. The neurology segment is expected to dominate during the forecast period on account of the increasing prevalence of neurological disorders along with neurovascular illness, and the growing aging population across the globe. Similarly, a comprehensive investigation of the multifaceted impact of cold atmospheric plasma in cancer treatment is also anticipated to boost market growth during the forecast period.
Major companies operating in the global plasma fractionation market are:
- Grifols S.A.
- Octapharma AG
- Intas Pharmaceuticals Ltd
- LFB S.A.
- Takeda Pharmaceutical Company Limited
- CSL Limited
- Biotest AG
- Kedrion S.p.A
- Bio Products Laboratory Ltd.’
- Bharat Serums and Vaccines Limited
In May 2022, Terumo Blood and Cell Technologies developed the newest production plant in Douglas County, Colorado. In the modern production plant, the cost is around USD $250 million, and the main company goal is to improve society via healthcare and service more people. In order to supply customers with source plasma collections, the 170,000 square foot facility will create single-use collection sets for the recently FDA-approved Rika Plasma Donation System (Rika).
In August 2020, Kedrion Biopharma (Italy) started developing a plasma-derived therapy for COVID-19 to make it available to patients in three to six months. The company worked in close collaboration with hospitals from some of the most COVID-infected regions of Italy.
In April 2020, Octapharma AG (Switzerland) launched a special project team to explore new therapies for COVID-19. The company also joined other leaders in plasma fractionation in a collaboration to develop a potential plasma-derived hyperimmune immunoglobulin therapy for treating COVID-19.
Customers can also request for 10% free customization on this report.
“The North America is expected to dominate in The Global Plasma Fractionation Market on account due to the increasing awareness about plasma therapy for the treatment of immunodeficiency disorder and the different advantages of plasma therapy across the region. Additionally, the rapid adoption of plasma proteins in immunology and neurology procedures and some other proteins are under development which will further propel the market growth over the years. Furthermore, the increasing risk of respiratory disorders and growing investment by major market players for the research and development activities across the region is further contributing to demand for plasma fractionation. Besides, availability of skilled health workers for managing the treatment and help patients is also expected to create lucrative opportunities for the market growth. ” said Mr. Karan Chechi, Research Director with TechSci Research, a research based global management consulting firm.
“Plasma Fractionation Market – Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented By Product (Albumin, Immunoglobulins, Coagulation Factors, Protease Inhibitors, Others), By Method (Centrifugation, Depth Filtration, Chromatography, Others), By Application (Neurology, Hematology, Oncology, Immunology, Others), By End User (Hospitals & Clinics, Academic & Research Institutes, Others), By Region and Competition”, has evaluated the future growth potential of global plasma fractionation market and provides statistics & information on market size, structure, and future market growth. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment decisions. Besides, the report also identifies and analyzes the emerging trends along with essential drivers, challenges, and opportunities in global plasma fractionation market.
Contact
Mr. Ken Mathews
708 Third Avenue,
Manhattan, NY,
New York – 10017
Tel: +1-646-360-1656
Email: [email protected]
Connect with us on Twitter – https://twitter.com/TechSciResearch
Connect with us on LinkedIn – https://www.linkedin.com/company/techsci-research
